Compare Adecoagro SA (AGRO) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adecoagro SA vs Cytokinetics Inc — how do they compare? Adecoagro SA trades at $9.1 (market cap $1.36B), while Cytokinetics Inc trades at $76.38 (market cap $10.63B). The key difference: Cytokinetics Inc is far larger — about 7.8× Adecoagro SA's market cap, and Adecoagro SA pays a 3.15% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| AGRO | CYTK | |
|---|---|---|
Market Cap | $1.36B | $10.63B |
Sector | Technology | Technology |
52-Week High | $15.25 | $87.26 |
52-Week Low | $7.13 | $34.31 |
Enterprise Value | $3.39B | $10.74B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO is trading at $9.01, down 6.73% today, with a bearish technical outlook despite attractive valuation ratios (P/S: 0.71, P/B: 0.77). The company reported mixed quarterly results with one beat and three misses in recent quarters, while showing improved adjusted EBITDA of $172.5 million in Q2 2026. Recent expansion via the Caarapó mill acquisition and Profertil integration provides growth catalysts amid commodity volatility.
The stock presents a value opportunity with below-market multiples but faces execution risks from negative earnings momentum and high leverage. Analyst consensus is mixed with 37.5% buy ratings and a $12.12 price target, suggesting 35% upside potential if operational improvements materialize.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
